Lomustine

Generic Name: Lomustine

Brand Names: Ceenu, Gleostine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₆ClN_₃O_₂

CAS Number: 13010-47-4

Unique Ingredient Identifier: 7BRF0Z81KG

Background: An alkylating agent of value against both hematologic malignancies and solid tumors.

Indication: For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.

Associated Conditions: Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma

Associated Therapies: -

Clinical Trials

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Early Phase 1

Withdrawn

Conditions: Recurrent Gliosarcoma
Recurrent Glioblastoma

Interventions: Drug: Liothyronine
Drug: Lomustine
Drug: Methimazole

First Posted Date: 2021-08-24

Last Posted Date: 2022-12-02

Lead Sponsor: Emory University

Registration Number: NCT05017610

Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma

Phase 2

Withdrawn

Conditions: First Progression of MGMT Promoter-methylated Glioblastoma

Interventions: Drug: Lomustine
Drug: Romiplostim

First Posted Date: 2021-06-22

Last Posted Date: 2023-05-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT04933942

Locations: 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸
Hospital Universitario 12 De Octubre, Madrid, Spain
🇨🇭
UniversitaetsSpital, Zürich, Switzerland

and more 2 locations

Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Drug: Lomustine
Drug: Imipramine Hydrochloride

First Posted Date: 2021-04-28

Last Posted Date: 2024-08-09

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 25

Registration Number: NCT04863950

Locations: 🇺🇸
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Phase 2

Active, not recruiting

Conditions: Glioblastoma Multiforme, Adult

Interventions: Drug: Berubicin
Drug: Lomustine

First Posted Date: 2021-02-21

Last Posted Date: 2024-06-21

Lead Sponsor: CNS Pharmaceuticals, Inc.

Target Recruit Count: 210

Registration Number: NCT04762069

Locations: 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
🇺🇸
Southern California Permanente Medical Group, Los Angeles, California, United States
🇺🇸
Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

and more 45 locations

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Phase 1

Recruiting

Conditions: Glioblastoma

Interventions: Drug: L19TNF
Drug: Lomustine

First Posted Date: 2020-10-05

Last Posted Date: 2024-04-08

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 142

Registration Number: NCT04573192

Locations: 🇩🇪
Klinikum rechts der Isar, München, Germany
🇩🇪
University Hospital Köln, Köln, Germany
🇫🇷
Hôpital Saint Louis, Paris, France

and more 12 locations

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Phase 2

Active, not recruiting

Conditions: Medulloblastoma

Interventions: Drug: Cisplatin
Drug: Sonidegib
Drug: Lomustine
Drug: Vincristine
Radiation: radiotherapy

First Posted Date: 2020-05-26

Last Posted Date: 2024-08-26

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 20

Registration Number: NCT04402073

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺
Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia
🇦🇺
Austin Health - Austin hospital, Melbourne, Australia

and more 47 locations

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Drug: VAL-083
Drug: VT1021
Drug: Troriluzole
Drug: Temozolomide
Drug: Regorafenib
Drug: Paxalisib
Biological: ADI-PEG 20
Drug: Lomustine
Radiation: Radiation

First Posted Date: 2019-05-31

Last Posted Date: 2024-12-02

Lead Sponsor: Global Coalition for Adaptive Research

Target Recruit Count: 1030

Registration Number: NCT03970447

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

and more 59 locations

Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients

Phase 2

Conditions: GBM

Interventions: Drug: Chlorogenic acid for Injection
Drug: Lomustine

First Posted Date: 2018-11-29

Last Posted Date: 2018-11-29

Lead Sponsor: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd

Target Recruit Count: 200

Registration Number: NCT03758014

Locations: 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

9-ING-41 in Patients with Advanced Cancers

Phase 2

Active, not recruiting

Conditions: Cancer
Pancreatic Cancer
Pancreatic Adenocarcinoma
Neoplasm, Breast
Neoplasms Pancreatic
Malignancies
Malignancies Multiple
Bone Cancer
Pancreatic Neoplasms
Neoplasm Metastasis

Interventions: Drug: 9-ING-41
Drug: Gemcitabine - 21 day cycle
Drug: Nab paclitaxel.
Drug: Doxorubicin.
Drug: Carboplatin.
Drug: Lomustine
Drug: Irinotecan
Drug: Gemcitabine - 28 day cycle
Drug: Paclitaxel.

First Posted Date: 2018-09-20

Last Posted Date: 2024-11-07

Lead Sponsor: Actuate Therapeutics Inc.

Target Recruit Count: 350

Registration Number: NCT03678883

Locations: 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇪🇸
Hospital Clinico U San Carlos (HSC), Madrid, Spain
🇪🇸
START Madrid-HM CIOCC Hospital Universitario, Madrid, Spain

and more 62 locations

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Phase 1

Completed

Conditions: Newly Diagnosed High Grade Glioma

Interventions: Drug: Nivolumab monotherapy
Drug: Temozolomide
Drug: Nivolumab
Radiation: conformal brain radiation therapy
Drug: Ipilimumab
Drug: 5-day Temozolomide
Drug: Bevacizumab
Drug: Lomustine

First Posted Date: 2018-02-07

Last Posted Date: 2023-11-08

Lead Sponsor: Saint John's Cancer Institute

Target Recruit Count: 49

Registration Number: NCT03425292

Locations: 🇺🇸
Saint John's Cancer Institute, Santa Monica, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy